Kids v Cancer’s Programs to Promote Pediatric Cancer Drug Development
To promote the development of drugs expressly for children with cancer and other rare diseases, Kids v Cancer authored and championed the Creating Hope Act, which became Section 908 of the FDA Safety and Innovation Act. This law creates a market-based incentive to spur pediatric cancer drug development. We are now working with the FDA, researchers and drug companies to ensure its full and effective implementation.
In addition, Kids v Cancer worked with the FDA to pursue a new interpretation of the Best Pharmaceuticals for Children’s Act, a framework law governing pediatric cancer research, which will allow the FDA to accelerate the development of drugs potentially useful in treating pediatric cancer.
Kids v Cancer is also working to identify areas of potential convergence between FDA and foreign regulatory practices that can help strengthen pediatric drug development.